Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Published:2014-06 Issue:7 Volume:15 Page:700-712
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kwon Eugene D,Drake Charles G,Scher Howard I,Fizazi Karim,Bossi Alberto,van den Eertwegh Alfons J M,Krainer Michael,Houede Nadine,Santos Ricardo,Mahammedi Hakim,Ng Siobhan,Maio Michele,Franke Fabio A,Sundar Santhanam,Agarwal Neeraj,Bergman Andries M,Ciuleanu Tudor E,Korbenfeld Ernesto,Sengeløv Lisa,Hansen Steinbjorn,Logothetis Christopher,Beer Tomasz M,McHenry M Brent,Gagnier Paul,Liu David,Gerritsen Winald R

Publisher

Elsevier BV

Subject

Oncology

Reference38 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group;Scher;J Clin Oncol,2008

3. Prostate cancer: ESMO Consensus Conference guidelines 2012;Horwich;Ann Oncol,2013

4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

5. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study;Fizazi;Lancet Oncol,2012

Cited by 1300 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. UQCRB and LBH are correlated with Gleason score progression in prostate cancer: Spatial transcriptomics and experimental validation;Computational and Structural Biotechnology Journal;2024-12

2. Exploring Radiotherapy as a Promising Alternative for Managing Advanced Upper Tract Urothelial Carcinoma: Rescuing Chemotherapy-Intolerant Patients;Clinical Genitourinary Cancer;2024-12

3. Advances in and prospects of immunotherapy for prostate cancer;Cancer Letters;2024-10

4. Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers;Nature Cancer;2024-09-06

5. A tumour‐associated macrophage‐based signature for deciphering prognosis and immunotherapy response in prostate cancer;IET Systems Biology;2024-08-13